Figure 1. Flowchart of Study Participants.

All randomized participants who received at least 1 dose of the trial compound (liraglutide or placebo) and who had at least 1 assessment after baseline were included in the efficacy analyses. Five participants from the liraglutide group and 1 from the placebo group were excluded from the analyses. Another participant in the liraglutide group was excluded after the first assessment and was therefore included in the efficacy analyses without completing the 16 weeks of treatment. All participants who were randomized and had received at least 1 dose of liraglutide or placebo were included in the safety analyses. BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); HbA_1c,hemoglobin A_1c. To convert hemoglobin A_1c to mmol/mol, subtract 2.15% and multiply by 10.929.